KYAN strategic collaboration

Learn more Oncology testing

Learn more Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients’ access to cancer testing

Expanding access to cancer testing

Mayo Clinic Laboratories has entered a strategic collaboration with KYAN Technologies to validate and provide Optim.AI™ testing across the United States. Optim.AI™ is an advanced ex vivo drug sensitivity platform that combines small data AI with biological experiments to identify effective cancer therapies. This collaboration empowers clinicians and researchers with actionable insights for personalized treatment and accelerates innovation in cancer care.

Transforming cancer care

Optim.AI™ delivers actionable insights into effective cancer therapies by combining AI-driven analysis with biological testing, helping clinicians personalize treatment plans.

Driving research innovation

This strategic collaboration accelerates oncology research by providing a validated platform for drug sensitivity testing, supporting breakthroughs in cancer drug development.

Empowering clinical decisions

By expanding access to Optim.AI™, we equip physicians with advanced tools to make informed, patient-specific decisions that inform outcomes and quality of life.

“This strategic collaboration with KYAN Technologies provides physicians access to robust diagnostic options, empowering informed decisions for better health outcomes.”

William Morice II, M.D., Ph.D., President and CEO, Mayo Clinic Laboratories